Elsevier

Journal of Controlled Release

Volume 324, 10 August 2020, Pages 440-449
Journal of Controlled Release

Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution

https://doi.org/10.1016/j.jconrel.2020.05.032Get rights and content

Highlights

  • We established three pairs of Ewing sarcoma PDX from the same patients at primary diagnosis and at later disease stages.

  • PDX pairs obtained at long-term relapse developed chemoresistance and showed decreased intracellular drug concentration.

  • Copy number alteration profiles of these PDX pairs suggested a common clonal origin of tumors at both disease stages.

  • Overexpression of P-glycoprotein was the likely cause of limited intracellular drug distribution in one of the tumor pairs.

Abstract

Ewing sarcoma is a bone and soft tissue tumor predominantly affecting adolescents and young adults. To characterize changes in anticancer drug activity and intratumor drug distribution during the evolution of Ewing sarcomas, we used immunodeficient mice to establish pairs of patient-derived xenografts (PDX) at early (initial diagnosis) and late (relapse or refractory progression) stages of the disease from three patients. Analysis of copy number alterations (CNA) in early passage PDX tissues showed that two tumor pairs established from patients which responded initially to therapy and relapsed more than one year later displayed similar CNAs at early and late stages. For these two patients, PDX established from late tumors were more resistant to chemotherapy (irinotecan) than early counterparts. In contrast, the tumor pair established at refractory progression showed highly dissimilar CNA profiles, and the pattern of response to chemotherapy was discordant with those of relapsed cases. In mice receiving irinotecan infusions, the level of SN-38 (active metabolite of irinotecan) in the intracellular tumor compartment was reduced in tumors at later stages compared to earlier tumors for those pairs bearing similar CNAs, suggesting that distribution of anticancer drug shifted toward the extracellular compartment during clonal tumor evolution. Overexpression of the drug transporter P-glycoprotein in late tumor was likely responsible for this shift in drug distribution in one of the cases.

Introduction

Ewing sarcoma is a malignancy of the bone and soft tissue of children, adolescents and young adults [1]. In pediatric patients, these tumors - even those (around 50%) classified as high-risk (i.e., those arising in the pelvis or axial skeleton –around 30–40%- and/or with metastases at diagnosis –around 20–30%) - respond well to first-line intensive high-dose chemotherapy [[2], [3], [4]]. For instance, three cycles of high-dose cyclophosphamide, doxorubicin and vincristine induce greater than 90% tumor necrosis in approximately 70% of high-risk patients [2]. In fact, more than 90% of high-risk Ewing sarcoma patients achieve complete remission upon intensive treatment including chemotherapy, radiotherapy and surgery [2,3]. However, more than 50% of patients with metastatic disease at diagnosis and 10–25% of patients with localized disease will relapse within five years of diagnosis [2,4,5]. Rescue pharmacotherapy regimens include camptothecins (irinotecan or topotecan) in combination with cyclophosphamide, temozolomide, or trabectedin [[6], [7], [8]], or taxane-based regimens [9]. Although these treatments actively slow disease, most relapsed tumors respond poorly (or for the short term) to these anticancer drugs, and long term survival for these patients is poor [2,5,10].

The evolution of tumors toward chemoresistance is likely due to the selective pressure of therapies [[11], [12], [13]]. Tumor cells exposed to treatment might be selected to: (i) upregulate oncogenes and downregulate tumor suppressor genes [14]; (ii) alter mitochondrial function to decrease apoptosis [15]; (iii) express drug efflux transporters such as the ATP-binding cassette (ABC) family including ABCB1 (P-glycoprotein/P-gp/MDR1), ABCG2 (Breast Cancer Resistance Protein/BCRP) and ABCC1 (Multidrug Resistance Protein 1/MRP1) [16]; (iv) undergo epithelial to mesenchymal transition [17]; and (v) change tumor dynamics and architecture (blood flow, interstitial fluid pressure, vessel distribution and phenotype, cell density and extracellular matrix) [18]. Some of these mechanisms, especially the expression of drug efflux transporters and changes in tumor dynamics and architecture, may lead to limited drug distribution in tumor cells, which is usually a neglected cause of drug resistance [19].

Whether tumor evolution produces changes in intratumoral drug pharmacokinetics upon intensive treatment in clinically relevant tumor models remains uncharacterized. Therapeutic effect is produced only if the drug can interact with its inner target in the tumor cell at sufficient concentration. However, there has not been in depth in vivo evaluation of anticancer drug distribution in the intracellular target and in other tumor compartments (extracellular and vascular) as it is technically challenging to accomplish [20,21].

To study the compartmental distribution of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan, in subcutaneous (s.c.) neuroblastoma patient-derived xenografts (PDX), we previously used the microdialysis-tumor homogenate method at the steady state (i.e., at constant drug concentration) in blood [22,23]. In vivo, irinotecan requires the action of the carboxylesterases to be rapidly converted to SN-38 in mice. This metabolite remains active in its lactone form, which predominates at acidic pH and coexists with the carboxylate (inactive) form under a pH-dependent equilibrium [22]. Irinotecan activity is known to be higher in mouse tumor models than in human patients, because there is a higher amount of carboxylesterases in mice [24]. Also, irinotecan/SN-38 biodistribution and activity is restrained by the activity of ABC efflux drug transporters in normal organs, such as the brain, and in tumors [25].

For these studies, we established pairs of Ewing sarcoma PDX models from three pediatric patients. One tumor of each pair was established at diagnosis, and the second was obtained upon relapse or refractory disease progression. We compared the chromosomal profile (copy number alterations; CNA) for each pair. Then, we addressed whether tumor evolution under treatment pressure led to changes in the compartmental intratumoral distribution of SN-38 in vivo, and in ABC transporter expression. We hypothesized that late tumors evolve to be drug resistant and less susceptible to the penetration of anticancer agents.

Section snippets

Establishment of paired Ewing sarcoma PDX models

Tumor biopsies were obtained under an Institutional Review Board-approved protocol at Sant Joan de Déu Hospital (SJD, Barcelona, Spain). Informed consent was obtained from all patients. Samples were obtained from each patient at different stages of treatment, either at diagnosis (early), at advanced (late) relapse or progression refractory stage, in order to establish “early” and “late” patient-matched PDX models. Xenografts were established s.c. in athymic nude mice (Envigo, Barcelona, Spain)

Paired PDX models and patient clinical exposure to irinotecan

We established three pairs of Ewing sarcoma PDX models from biopsies obtained at diagnosis (early) and relapse/progressive refractory (late) stage from three individuals with Ewing sarcoma. Clinical data including EWSR1-FLI1 gene fusions are detailed in Table 1. Patients 1 and 2 achieved complete remission after treatment but relapsed more than one year after diagnosis, off treatment. Patient 3 did not achieve remission and a late biopsy was obtained during refractory progression on treatment.

Discussion

Our studies in patient-matched pairs of PDX models of Ewing sarcoma addressed questions related to changes in drug efficacy and pharmacokinetics within tumor compartments upon tumor evolution. Tumor pairs from patients 1 and 2 after relapse showed the same fusion genes and subtle chromosomic changes compared to early tumor pairs, but were more prone to become chemoresistant and less susceptible to intracellular drug distribution. The patient-matched tumor pair obtained from primary refractory

Conclusion

In summary, using a unique set of clinically relevant PDX pairs established at early and late tumor stages, we have identified that drug concentration in Ewing sarcoma tumor cells becomes restricted during tumor evolution under treatment pressure. We observed this in two cases in which CNAs in early and late xenografts were similar, suggesting a common clonal origin. Our results should be taken cautiously due to the low number of cases, but they might be clinically relevant to predict response

Declaration of Competing Interest

None.

Acknowledgements

The work at Hospital Sant Joan de Deu was supported by associations of parents and families of children with cancer. The work of EdA was supported by the AECC Scientific Foundation (GCB13-1578), ISCIII-FEDER (PI14/01466 and PI17/00464), CIBERONC (CB16/12/00361), Asociación Pablo Ugarte and Fundación María García Estrada. The work of JM was supported by the AECC Scientific Foundation (GCB13-1578) and Asociación Pablo Ugarte. The work of AMC was supported by grants from the AECC Scientific

References (45)

  • L.M. Wagner et al.

    Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma

    Pediatr. Blood Cancer

    (2007)
  • J. Herzog et al.

    Trabectedin followed by irinotecan can stabilize disease in advanced translocation-positive sarcomas with acceptable toxicity

    Sarcoma

    (2016)
  • R.L. Saylors et al.

    Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a pediatric oncology group phase II study

    J. Clin. Oncol.

    (2001)
  • J. Mora et al.

    Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel

    J. Pediatr. Hematol. Oncol.

    (2009)
  • C. Rodriguez-Galindo et al.

    Survival after recurrence of Ewing tumors

    Cancer

    (2002)
  • B.E. Johnson et al.

    Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma

    Science

    (2014)
  • A. Schramm et al.

    Mutational dynamics between primary and relapse neuroblastomas

    Nat. Genet.

    (2015)
  • B.D. Crompton et al.

    The genomic landscape of pediatric Ewing sarcoma

    Cancer Discov.

    (2014)
  • H.Y. Huang et al.

    Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse

    J. Clin. Oncol.

    (2005)
  • H. Brahmbhatt et al.

    Molecular pathways: leveraging the BCL-2 interactome to kill Cancer cells--mitochondrial outer membrane permeabilization and beyond

    Clin. Cancer Res.

    (2015)
  • S. Lamouille et al.

    Molecular mechanisms of epithelial-mesenchymal transition

    Nat. Rev. Mol. Cell Biol.

    (2014)
  • K.J. Patel et al.

    Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues

    Cancer Chemother. Pharmacol.

    (2013)
  • Cited by (0)

    1

    Equal contribution.

    View full text